Financial/Commercial Relationships Disclosures

CREDIT STATEMENT IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide

continuing medical education for physicians.

IASLC CME designates this live activity for a maximum of 10.5 AMA PRA Category 1 Credits™. Physicians

should claim only the credit commensurate with the extent of their participation in the activity.

FINANCIAL SUPPORT This educational activity was commercially supported by: Merck; Genetech; Astrazeneca; Astellas; Bristol-

Meyers Squibb, Boehringer Ingelheim, Novartis, Pfizer, Lilly, Biodesix and Guardant 360.

Financial/Commercial Relationships DISCLOSURES

All individuals able to influence or control content of any CME certified activity that will be presented were

required to complete a Financial Relationships/Conflicts of Interest Disclosure Form prior to the live activity.

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or

their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a

commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or

used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and

teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria,

ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or

any other financial benefit. Financial benefits are usually associated with roles such as employment, management

position, independent contractor (including contracted research and clinical trials), consulting, speaking and

teaching, membership on advisory committees or review panels, board membership, and other activities for

which remuneration is received or expected.

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure

balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information

under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to

inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or

referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/peer reviewers et. al. conflicts of interest were

identified, reviewed and resolved from all individuals involved in the development or able to influence and control

the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity

being delivered to learners. Any individual who failed or refused to disclose relevant financial relationships was

disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics

Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of

the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care

recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and

related materials that promote improvements or quality in health care and not a specific proprietary business

interest of a commercial entity.

The following Financial Disclosures are from the, reviewers , speakers, planning committee members (et.al.) their

spouse/life partner have disclosed regarding financial interest/arrangement or affiliation with any commercial

interests that produce, market, re-sell, or distribute healthcare goods or services for patients that are relevant to

this presentation(s) or that have provided commercial support for this continuing medical education activity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide

continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 10.5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FINANCIAL SUPPORT

This educational activity was commercially supported by: Merck; Genetech; Astrazeneca; Astellas; Bristol-

Meyers Squibb, Boehringer Ingelheim, Novartis, Pfizer, Lilly, Biodesix and Guardant 360.

GOAL & PURPOSE

This symposium is an educational and scientific event which, due to its multidisciplinary nature, will cover all

aspects of the management of lung cancers, mesothelioma, thymic and other thoracic malignancies.

Participants will learn about tobacco control and smoking cessation programs and how to implement them in

their daily practice. Participants will update their knowledge on early detection and screening.

The symposium will provide lectures on accurate diagnosis including molecular diagnosis, state-of-the-art

treatment of thoracic malignancies, and recent diagnostic and therapeutic advances. Participants will learn about

palliative care and its implementation in daily practice.

Participants will be informed about the possibilities for continuous medical education. They will learn about

clinical trial designs and how to become successful investigators of co-operative research groups. The Conference

will also allow participants to be better informed about patient support and advocacy groups.

TARGET AUDIENCE

This CME activity is designed to meet the educational needs of healthcare professionals who diagnose and treat

patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation

oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

LEARNING OBJECTIVES

Examine evidence-based therapeutic regimens for early stage and locally advanced NSCLC.

Distinguish evidence-based therapeutic regimens for metastatic NSCLC based on biomarker status

and patient/tumor characteristics.

Define best practices regarding the application of targeted therapies for metastatic NSCLC in frontline and then

subsequent settings following acquired resistance to the targeted therapy.

Describe current and emerging immunotherapy strategies in the context of clinical trials findings and patient

selection in metastatic NSCLC.

Integrate clinical data on maintenance therapy in NSCLC to determine which patients would benefit most from a

maintenance regimen.

Review the clinical significance of optimal biopsy, specimen flow and molecular testing for

personalized medicine in non-academic settings.

Illustrate the molecular pathways that hold promise for therapeutic intervention.

Outline current therapeutic approaches for limited and extensive small cell lung cancer (SCLC).

Describe current therapeutic approaches for patients with mesothelioma and thymoma.

Predict optimal and best practice approaches for supportive and palliative care of patients with thoracic cancers.

Evaluate the support and survivorship resources available for lung cancer patients and their families.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and

their own professional development. The information presented in this activity is not meant to serve as a guideline

for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or

suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and

possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and

comparison with recommendations of other authorities.

Thank you for your participation.

Role(s) in the educational

activity: Full Name

I ( my family/significant other) have/had BOTH

(1) a personal financial relationship(s) with a

commercial interest and (2) will control

educational content about the products of the

commercial interest(s).

Reviewer

Planners

Invited Speakers

Alex Adjei, MD, PhD-

Nothing to disclose

Pia Hirsch

Carlos Ferreira

Nothing to disclose

Nothing to disclose

Ahmed, Zaheer Nothing to disclose

Albain, Kathy Nothing to disclose

Bauer, Todd Nothing to disclose

Bonomi, Philip Advisory Boards or Data Monitoring

Committees: Astra Zeneca,Biodesics, Eli Lilly,

Merck, Pfizer, Roche Genentech, Trovagene

Brahmer, Julie Research grants from BMS,

MedImmune/AstraZeneca, Merck. Consultant

for BMS, Celegene, Lilly, Merck

Advisory Board/Consulting: BMS

(uncompensated), Celgene, Eli Lilly, Merck;

Grants: BMS, MedImmune/AstraZeneca,

Merck

Bretta McCall Research Support from The Anne and Wayne

Gittinger Trust

Choi, Noah Nothing to disclose

Chris Draft Nothing to disclose

Corey Langer Speaker/Advisory board, Honoraria and

research contract from: DSMC, Lilly, Abbvie,

Synta, Swog, Peregine,-Advisory Board//

AdvantageneInovio, Merck, Celgene, Ariad-

Research Grant// Genetech, Roche-

Honorarium// Merck, Astrazeneca, Bristol-

Meyers Squibb, Lilly, Clovis, Ariad, Celgene,

Genentech, Roche,Clamient

Dahlberg, Suzanne Northing to disclose

Decamp, Malcolm Nothing to disclose

Diehn, Max Nothing to Disclose

Donington, Jessica Nothing to disclose

Feliciano, Josephine Nothing to Disclose

Fidler, Mary Jo Genentech: self-speaker, husband consultant

receiving bulk of salary from them; Celgene:

speaker, advisor (self) Novartis speaker (self)

Astrazeneca advisor (self)

Gandara, David AstraZeneca/Medi, Bristol-Myers Squibb,

Clovis, Genentech, Johnson & Johnson, Lilly,

Merck, Novartis: Research Grants to

Institution; AstraZeneca, Boehringer-

Ingelheim, Celgene, Clovis, Genentech,

Guardant Health, Lilly, Merck, Novartis,

Pfizer, Synta consultanting with honorarium

received

Gaspar, Laurie Nothing to disclose

Gaurav Marwaha Nothing to disclose

Gomez, Daniel Nothing to disclose

Harkenrider, Matthew Nothing to disclose

Hirsch, Fred R. Advisory boards: Genentech/Roche, Lilly,

AstraZeneca, BMS, Merck, Ventana, Novartis,

HTG

Hoffman, Philip Nothing to disclose

Horn, Leora BMS, BI, Xcovery unpaid consulting, Abbvie,

Genentech, Lilly, Merck - paid consulting

Hussein, Maen Nothing to disclose

Inga Lennes Nothing to disclose

James Yao Speaker/Advisory Board and Research Grant

from: Novartis

Jeter, Melenda Nothing to disclose

Jiexia Zhang Nothing to disclose

John Heymack Nothing to disclose

Kamel, Mohamed Nothing to disclose

Kelly, Karen Advisory Board-Ariad, AstraZeneca, BMS,

Boehringer Ingelheim, Clovis, Genentech, Lilly;

Research Support-AbbVie, Celgene, EMD

Serono, Genentech, Gilead, Lilly, Millennium,

Novartis; Royalty-UpToDate

Kindler, Hedy Advisory Board: Bayer, Merck, Aduro,

MedImmune, Genentech; Research funding:

Merck, MedImmune, GSK, Aduro, Bayer

Kujtan, Lara Nothing to disclose

Leighl, Natasha Nothing to disclose

Levine, Stacie Nothing to disclose

Osarogiagbon,

Raymond

Roche/Genentech (speaker, advisory board);

Pfizer (stock); Eli Lilly (stock)

Oxnard, Geoffrey Consulting fees from AstraZeneca, Ariad,

Boehringer-Ingelheim, Genentech, Inivata;

honoraria from AstraZeneca and Boehringer-

Ingelheim; patent pending on an approach

toward genotyping of plasma cell-free DNA.

Patel, Jyoti Nothing to disclose

Pennell, Nathan AstraZeneca, advisory board; Boerhinger

Ingelheim, advisory board

Peter Hawkins Nothing to disclose

Osarogiagbon, Raymond Nothing to disclose

Powell, Charles Genentech- Consultant; Siemens-Consultant

Rahouma, Mohamed Nothing to disclose

Rimm, David Consultant/Advisor to Astra Zeneca, Bethyl

Labs, Biocept, BMS, Cernostics, FivePrime,

Genoptix, Metamark Genetics, Novartis,

OptraScan, Perkin Elmer and Ultivue I hold

equity in Metamark Genetics and PixelGear

Cepheid, Genoptix, Gilead Sciences, Pierre

Fabre, Perkin Elmer and OncoplexDx fund

research in my lab.

Roy Herbst Speakers/Advisory Board and Honoraria form

Astrazeneca, Lilly, Genetech and Merck

Sabari, Joshua Nothing to disclose

Scott Antonia Speakers or Advisory Board; Ownership

Interest (stocks, or stock options, or other

ownership interest excluding diversified

mutual funds); Honoraria; Royalty, receipt of

Intellectual Property Rights/Patent Holder for

BMS, AZ, cbmg, merck

Shanshal, Mohamed Nothing to disclose

Shaw, Alice Advisory board: Pfizer, Novartis,

Genentech/Roche, Ariad, EMD Serono,

Blueprint medicine, LOXO. Consultant:

Ignyta, Daiichi-sankyo, Taiho

Sheffield, Kristin Eli Lilly and Company - employee and own

stock

Steliga, Matthew Nothing to disclose

Supreet Kaur Nothing to disclose

Tarhoni, Imad Nothing to disclose

Vallieres, Eric Nothing to Disclose

Vokes, Everett Amgen, AstraZeneca, Boehringer-Ingelheim,

Celgene, Eli Lilly, Genentech, Merck, Synta,

VentiRx - All Consultant/Advisory Roles

Wakelee, Heather Consultant: Peregrine, ACEA, Pfizer, Helsinn,

Genentech/Roche (uncompensated), Clovis

(uncompensated), Lilly (uncompensated):

Research/Grant Support: Clovis, Exelixis,

AstraZeneca/Medimmune, Genentech/Roche,

BMS, Gilead, Novartis, Xcovery, Pfizer,

Celgene, Gilead, Pharmacyclics, Lilly

Witta, Samir Nothing to disclose

Xiaomin Niu Nothing to disclose

Yankelevitz, David Nothing to disclose

TO RECEIVE CME CREDIT:

Upon completion of the electronic evaluation link the CME Certificate will be ready for you to print or save for your records. This information is

used not only to evaluate the present activity, but also to plan for future programs. Participants who complete a post-test along with an

evaluation will receive 10.5 AMA PRA Category 1 Credit(s)™ for each completed webinar